Bavarian Nordic A/S has agreed with GlaxoSmithKline (GSK) not to pursue a collaboration for the production and marketing of IMVAMUNE®, a third generation smallpox vaccine, as contemplated in a Memorandum of Understanding signed by the two companies in 2004, signed to ensure sufficient production capacity and distribution of IMVAMUNE® at a time where Bavarian Nordic's own production facility was not established. Now Bavarian Nordic has the capacity to produce the expected RFP-III order.
Attachments
